Johannes Berkhof (Netherlands)

Amsterdam UMC, Vrije Universiteit Amsterdam Epidemiology and Biostatistics

Dr. Johannes Berkhof is the head of the department of Epidemiology and Biostatistics at the Amsterdam UMC and his background is in econometrics. He has conducted several cost-effectiveness studies on HPV vaccination and screening and recently led a screening study of 16,000 women randomized to primary HPV self-sampling or clinician-sampling (IMPROVE study). He has co-authored >200 papers in methodological and medical journals. Dr. Berkhof is also the coordinator of the EU-funded RISCC consortium on risk-based screening in Europe.

Presenter of 1 Presentation

Conference Calendar

Workshop 4: Vaccination Hall A

Vaccine pricing and policy implications (ID 61)

Session Date

07/20/2020

Session Time

15:30 - 16:55

Room

Hall A

Session Type

Interdisciplinary

Session Name

Workshop 4: Vaccination

Lecture Time

16:33 - 16:53

Presenter

Johannes Berkhof (Netherlands)

Authors

Johannes Berkhof (Netherlands)

Moderator of 2 Sessions

Conference Calendar

Public Health Oral Session

00860 - Oral Session 11: MODELLING II. Modelling and economic analyses for cervical cancer elimination (ID 48)

Session Type

Public Health Oral Session

Session Date

07/23/2020

Session Time

08:30 - 09:55

Room

Hall E

Chair(s)

Watch Stream
Session Webcast

Session Webcast

[{"name":"MULTI-COHORT HPV VACCINATION ENABLES CERVICAL CANCER ELIMINATION DURING THIS CENTURY FOR REGIONS WITH HIGH HIV PREVALENCE \u003Csmall\u003E(ID 1041)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":1041,"presentation":"MULTI-COHORT HPV VACCINATION ENABLES CERVICAL CANCER ELIMINATION DURING THIS CENTURY FOR REGIONS WITH HIGH HIV PREVALENCE \u003Csmall\u003E(ID 1041)\u003C\/small\u003E","session":"Oral Session 11: MODELLING II. Modelling and economic analyses for cervical cancer elimination","presenter":"Cara Bayer (United States of America)","photo":""},"playlist":[{"name":"MULTI-COHORT HPV VACCINATION ENABLES CERVICAL CANCER ELIMINATION DURING THIS CENTURY FOR REGIONS WIT","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/48\/P1041_S1060_Cara Bayer.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/48\/P1041_S1060_Cara Bayer.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/48\/2579FC8D.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/48\/P1041_S1060_Cara Bayer.vtt"}]},{"name":"BUDGET OPTIMISATION STRATEGY TOWARDS ELIMINATION OF CERVICAL CANCER UNDER AGEING, URBANISATION AND SEXUAL OPENING TRANSITION SETTINGS FROM 2015 TO 2100 IN CHINA: A MODELLING STUDY \u003Csmall\u003E(ID 227)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":227,"presentation":"BUDGET OPTIMISATION STRATEGY TOWARDS ELIMINATION OF CERVICAL CANCER UNDER AGEING, URBANISATION AND SEXUAL OPENING TRANSITION SETTINGS FROM 2015 TO 2100 IN CHINA: A MODELLING STUDY \u003Csmall\u003E(ID 227)\u003C\/small\u003E","session":"Oral Session 11: MODELLING II. Modelling and economic analyses for cervical cancer elimination","presenter":"Changfa Xia (China)","photo":""},"playlist":[{"name":"BUDGET OPTIMISATION STRATEGY TOWARDS ELIMINATION OF CERVICAL CANCER UNDER AGEING, URBANISATION AND S","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/48\/P227_S1060_BUDGET OPTIMISATION STRATEGY.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/48\/P227_S1060_BUDGET OPTIMISATION STRATEGY.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/48\/9D61AB94.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/48\/P227_S1060_BUDGET OPTIMISATION STRATEGY.vtt"}]},{"name":"COST-EFFECTIVENESS OF CERVICAL CANCER ELIMINATION IN LOW- AND MIDDLE-INCOME COUNTRIES (LMICS): EXAMPLE FROM VIETNAM \u003Csmall\u003E(ID 819)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":819,"presentation":"COST-EFFECTIVENESS OF CERVICAL CANCER ELIMINATION IN LOW- AND MIDDLE-INCOME COUNTRIES (LMICS): EXAMPLE FROM VIETNAM \u003Csmall\u003E(ID 819)\u003C\/small\u003E","session":"Oral Session 11: MODELLING II. Modelling and economic analyses for cervical cancer elimination","presenter":"Diep Thi Ngoc Nguyen (Australia)","photo":""},"playlist":[{"name":"COST-EFFECTIVENESS OF CERVICAL CANCER ELIMINATION IN LOW- AND MIDDLE-INCOME COUNTRIES (LMICS): EXAMP","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/48\/819 Diep Thi Ngoc.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/48\/819 Diep Thi Ngoc.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/48\/ED538045.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/48\/819 Diep Thi Ngoc.vtt"}]},{"name":"COST-EFFECTIVENESS OF COMMUNITY HEALTH CAMPAIGN STRATEGIES TO DELIVER SELF-COLLECTED HUMAN PAPILLOMAVIRUS-BASED TESTING FOR CERVICAL CANCER SCREENING IN KENYA \u003Csmall\u003E(ID 271)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":271,"presentation":"COST-EFFECTIVENESS OF COMMUNITY HEALTH CAMPAIGN STRATEGIES TO DELIVER SELF-COLLECTED HUMAN PAPILLOMAVIRUS-BASED TESTING FOR CERVICAL CANCER SCREENING IN KENYA \u003Csmall\u003E(ID 271)\u003C\/small\u003E","session":"Oral Session 11: MODELLING II. Modelling and economic analyses for cervical cancer elimination","presenter":"Jessica Y. Islam (United States of America)","photo":""},"playlist":[{"name":"Jessica Islam - IPVC20 - 271","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/48\/Jessica Islam - IPVC20 - 271.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/48\/Jessica Islam - IPVC20 - 271.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/48\/74ABFCB.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/48\/Jessica Islam - IPVC20 - 271.vtt"}]},{"name":"ACCEPTABLE UNIT PRICE DIFFERENCES BETWEEN HPV VACCINES FOR SEX-NEUTRAL VACCINATION ARE LOWER THAN FOR GIRLS-ONLY \u003Csmall\u003E(ID 921)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":921,"presentation":"ACCEPTABLE UNIT PRICE DIFFERENCES BETWEEN HPV VACCINES FOR SEX-NEUTRAL VACCINATION ARE LOWER THAN FOR GIRLS-ONLY \u003Csmall\u003E(ID 921)\u003C\/small\u003E","session":"Oral Session 11: MODELLING II. Modelling and economic analyses for cervical cancer elimination","presenter":"Simopekka V\u00e4nsk\u00e4 (Finland)","photo":""},"playlist":[{"name":"ACCEPTABLE UNIT PRICE DIFFERENCES BETWEEN HPV VACCINES FOR SEX-NEUTRAL VACCINATION ARE LOWER THAN FO","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/48\/Simopekka V\u00e4nsk\u00e4 - IPVC20 - 921 - ACCEPTABLE UNIT PRICE DIFFERENCES BETWEEN HPV VACCINES FOR SEX-NEUTRAL VACCINATION ARE LOWER THAN FOR GIRLS-ONLY_new.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/48\/Simopekka V\u00e4nsk\u00e4 - IPVC20 - 921 - ACCEPTABLE UNIT PRICE DIFFERENCES BETWEEN HPV VACCINES FOR SEX-NEUTRAL VACCINATION ARE LOWER THAN FOR GIRLS-ONLY_new.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/48\/3FDAFED9.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/48\/Simopekka V\u00e4nsk\u00e4 - IPVC20 - 921 - ACCEPTABLE UNIT PRICE DIFFERENCES BETWEEN HPV VACCINES FOR SEX-NEUTRAL VACCINATION ARE LOWER THAN FOR GIRLS-ONLY_new.vtt"}]},{"name":"CATCH-UP VACCINATION HAS GREATER INCREMENTAL IMPACT ON CERVICAL CANCER INCIDENCE IN HIGH VS. MEDIUM HIV BURDEN SETTING \u003Csmall\u003E(ID 1060)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":1060,"presentation":"CATCH-UP VACCINATION HAS GREATER INCREMENTAL IMPACT ON CERVICAL CANCER INCIDENCE IN HIGH VS. MEDIUM HIV BURDEN SETTING \u003Csmall\u003E(ID 1060)\u003C\/small\u003E","session":"Oral Session 11: MODELLING II. Modelling and economic analyses for cervical cancer elimination","presenter":"Gui Liu (United States of America)","photo":""},"playlist":[{"name":"CATCH-UP VACCINATION HAS GREATER INCREMENTAL IMPACT ON CERVICAL CANCER INCIDENCE IN HIGH VS. MEDIUM ","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/48\/GMT20200624-044837_Gui-Liu-IP_1760x900-0.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/48\/GMT20200624-044837_Gui-Liu-IP_1760x900-0.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/48\/3AFE5097.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/48\/GMT20200624-044837_Gui-Liu-IP_1760x900-0.vtt"}]}]

Clinical Science Oral Session

01070 - Oral Session 11: Self Sampling (ID 81)

Session Type

Clinical Science Oral Session

Session Date

07/24/2020

Session Time

16:00 - 17:00

Room

Hall B

Chair(s)

Watch Stream
Session Webcast

Session Webcast

[{"name":"SELF-SAMPLING COMBINED WITH THE COBAS HPV TEST IN A COHORT OF 13,111 WOMEN UTILIZING A MIDWIFERY NETWORK IN GREECE. FINAL RESULTS OF THE GRECOSELF STUDY. \u003Csmall\u003E(ID 152)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":152,"presentation":"SELF-SAMPLING COMBINED WITH THE COBAS HPV TEST IN A COHORT OF 13,111 WOMEN UTILIZING A MIDWIFERY NETWORK IN GREECE. FINAL RESULTS OF THE GRECOSELF STUDY. \u003Csmall\u003E(ID 152)\u003C\/small\u003E","session":"Oral Session 11: Self Sampling","presenter":"Kimon Chatzistamatiou (Greece)","photo":""},"playlist":[{"name":"SELF-SAMPLING COMBINED WITH THE COBAS HPV TEST IN A COHORT OF 13,111 WOMEN UTILIZING A MIDWIFERY NET","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/81\/152.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/81\/152.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/81\/F7C8470F.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/81\/152.vtt"}]},{"name":"PATIENT CHARACTERISTICS THAT MODIFY THE EFFECTIVENESS OF A MAILED HPV SELF-SAMPLING KIT INTERVENTION IN A US-HEALTHCARE-SYSTEM-BASED PRAGMATIC RANDOMIZED TRIAL \u003Csmall\u003E(ID 602)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":602,"presentation":"PATIENT CHARACTERISTICS THAT MODIFY THE EFFECTIVENESS OF A MAILED HPV SELF-SAMPLING KIT INTERVENTION IN A US-HEALTHCARE-SYSTEM-BASED PRAGMATIC RANDOMIZED TRIAL \u003Csmall\u003E(ID 602)\u003C\/small\u003E","session":"Oral Session 11: Self Sampling","presenter":"Rachel L. Winer (United States of America)","photo":""},"playlist":[{"name":"PATIENT CHARACTERISTICS THAT MODIFY THE EFFECTIVENESS OF A MAILED HPV SELF-SAMPLING KIT INTERVENTION","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/81\/Rachel Winer - IPVC20 - PRESENTATION id 602.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/81\/Rachel Winer - IPVC20 - PRESENTATION id 602.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/81\/5E554BCE.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/81\/Rachel Winer - IPVC20 - PRESENTATION id 602.vtt"}]},{"name":"EVALUATION OF COBAS HPV AND SEQHPV NGS ASSAYS IN THE CHINESE MULTI-CENTER SCREENING TRIAL (CHIMUST) \u003Csmall\u003E(ID 1200)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":1200,"presentation":"EVALUATION OF COBAS HPV AND SEQHPV NGS ASSAYS IN THE CHINESE MULTI-CENTER SCREENING TRIAL (CHIMUST) \u003Csmall\u003E(ID 1200)\u003C\/small\u003E","session":"Oral Session 11: Self Sampling","presenter":"Jerome Belinson (United States of America)","photo":""},"playlist":[{"name":"EVALUATION OF COBAS HPV AND SEQHPV NGS ASSAYS IN THE CHINESE MULTI-CENTER SCREENING TRIAL (CHIMUST)","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/81\/Jerome L Belinson - IPVC20 - 1200.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/81\/Jerome L Belinson - IPVC20 - 1200.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/81\/9CEC007.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/81\/Jerome L Belinson - IPVC20 - 1200.vtt"}]},{"name":"SELF-COLLECTION OR PRACTITIONER-COLLECTED EVALUATION (SCOPE) STUDY: EXAMINING WHETHER USING A COPAN FLOQSWAB IS NON-INFERIOR TO PRACTIONER-COLLECTED SPECIMENS ACROSS SIX HPV ASSAYS \u003Csmall\u003E(ID 687)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":687,"presentation":"SELF-COLLECTION OR PRACTITIONER-COLLECTED EVALUATION (SCOPE) STUDY: EXAMINING WHETHER USING A COPAN FLOQSWAB IS NON-INFERIOR TO PRACTIONER-COLLECTED SPECIMENS ACROSS SIX HPV ASSAYS \u003Csmall\u003E(ID 687)\u003C\/small\u003E","session":"Oral Session 11: Self Sampling","presenter":"Marion Saville (Australia)","photo":"https:\/\/cslide.ctimeetingtech.com\/global_storage\/media\/content\/ipvc20\/persons\/photos\/4338.jpg"},"playlist":[{"name":"SELF-COLLECTION OR PRACTITIONER-COLLECTED EVALUATION (SCOPE) STUDY: EXAMINING WHETHER USING A COPAN ","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/81\/Marion Saville IPVC20 687 SELF-COLLECTION OR PRACTITIONER.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/81\/Marion Saville IPVC20 687 SELF-COLLECTION OR PRACTITIONER.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/81\/DBC7137D.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/81\/Marion Saville IPVC20 687 SELF-COLLECTION OR PRACTITIONER.vtt"}]}]